China approves Sinovac Biotech COVID-19 vaccine for general public use
07 February, 2021
Sinovac Biotech said on Saturday (Feb 6) that its unit's COVID-19 vaccine has been formally approved for use by everyone by China's medical items regulator.
It marks the second COVID-19 vaccine green-lighted for public work with in China, after a go developed by a good Beijing institute affiliated to state-owned China National Pharmaceutical Group (Sinopharm) was approved in December.
Both vaccines have been found in China's vaccination programme mainly targeting key groups deemed to be at larger risk of contact with the virus.
Indonesia, Turkey, Brazil, Chile, Colombia, Uruguay and Laos contain granted emergency authorisation for the CoronaVac vaccine developed by Sinovac Lifestyle Sciences, Sinovac said found in a news release.
Acceptance of the two-dose program by China's National Medical Products Administration is based on the results from 8 weeks of late-stage clinical trials overseas, from which the ultimate analysis data hasn't yet been obtained, Sinovac said.
Sinovac Lifestyle Sciences is likely to manage to produce a lot more than 1 billion doses each year in the sort of bulk ingredient by February, it said in a assertion.
It really is expanding its potential to load vaccine into vials and syringes, which currently lags its vaccine manufacturing capacity.
VARIED EFFICACY RATES
Sinovac's vaccine has been tested in Period III clinical trials found in countries including Brazil, Turkey and Indonesia, where varied efficacy readings have been released separately.
The vaccine was found 50.65 % effective against COVID-19 disease in the Brazil trial which got recruited 12,396 health employees older than 18 by Dec 16 and recorded 253 cases, Sinovac said in a statement on Friday.
The achievement rate from the Turkey trial was 91.25 %, local researchers said, based on a preliminary analysis of 29 cases. There was a 65.3 % efficacy rate in the Indonesia trial.
Brazil's even more rampant epidemic, and the trial's concentrate on medical personnel, are elements which Sinovac believe might have lowered the efficacy rate observed in data from there, a good person familiar with the problem told Reuters last month.
The Brazil trial also found the vaccine was 83.7 % effective against the condition that requires treatment, and 100 % effective against hospitalization, severe cases and death in the same trial, Sinovac explained on Friday.
The protection rate was practically 70 per cent based on observation of a small sub-group in the Brazil trial, in which participants received both doses at a three-week interval instead of two weeks apart for some participants, Sinovac said previous month.
Source: